Camber Pharmaceuticals has secured FDA approval for its Abbreviated New Drug Application of Methadone Hydrochloride, positioning the company to enter the critical market for opioid dependency and pain management therapies. This authorization is expected to drive down healthcare costs by offering a competitive alternative to branded products and increasing generic supply.